Cyclacel implements 1-for-15 reverse stock split effective July 7, 2025

Bio Green Med Solution, Inc.

Reverse split at 1:15 ratio, effective July 7, 2025; trading begins split-adjusted that day.
Pre-split shares outstanding: 23,759,475; post-split: approx. 1,583,965 shares.
Split approved by board and stockholders; aims to meet Nasdaq minimum bid price requirement.
No fractional shares; rounding up or down to the nearest whole share.
New CUSIP 23254L876; ticker remains CYCC on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bio Green Med Solution, Inc.: Filed Certificate of Amendment to implement a one-for-fifteen reverse stock split to meet Nasdaq bid price requirements (effective 2025-07-07).

Change: charter amendment
Effective: 2025-07-07

Exact text from the filing

On July 2, 2025, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed an amendment to its Certificate of Incorporation (“Certificate of Amendment”) to implement a one-for-fifteen reverse stock split.

View on SEC.gov

274 governance changes filed in the last 30 days. Browse all governance changes →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-017479

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.